Regenerative Therapy and Immune Modulation Using Umbilical Cord Blood-Derived Cells

Area of Science:

• Stem Cell Biology
• Regenerative Medicine
• Hematopoietic Transplantation

Background:

• Umbilical cord blood (UCB) is a crucial source for hematopoietic stem cell transplantation (HSCT) since 1988.
• UCB's nonhematopoietic progenitor cells are increasingly recognized for regenerative and immunomodulatory applications.
• Emerging uses expand beyond treating blood diseases and metabolic disorders.

Purpose of the Study:

• To provide an updated review of clinical and preclinical studies on UCB-derived cells.
• To explore novel applications of UCB cells in regenerative therapy and immune modulation.
• To highlight UCB's potential in gene therapy and as a source for therapeutic reagents.

Main Methods:

• Review of clinical and preclinical studies on UCB-derived cells.
• Analysis of UCB cell applications in regenerative medicine and immune modulation.
• Investigation of UCB cells as vectors for gene therapy and microvesicle delivery.

Main Results:

• UCB-derived cells, including mesenchymal stromal cells and endothelial-like progenitor cells, show significant therapeutic potential.
• UCB cells are being utilized as delivery vehicles for gene therapy and therapeutic agents.
• UCB is a valuable source of reagents for regenerative medicine applications.

Conclusions:

• Umbilical cord blood has diverse applications beyond HSCT, driven by its nonhematopoietic stem and progenitor cells.
• The use of UCB cells in regenerative therapy, immune modulation, and gene therapy is rapidly expanding.
• UCB holds immense potential for future therapeutic innovations in a fast-evolving field.